J Med Microbiol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kirby, A.
Right arrow Articles by Nistal de Paz, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kirby, A.
Right arrow Articles by Nistal de Paz, C.
Agricola
Right arrow Articles by Kirby, A.
Right arrow Articles by Nistal de Paz, C.
J Med Microbiol 58 (2009), 376-380; DOI: 10.1099/jmm.0.006486-0
© 2009 Society for General Microbiology
ISSN 0022-2615

Case Report

In vivo development of heterogeneous glycopeptide-intermediate Staphylococcus aureus (hGISA), GISA and daptomycin resistance in a patient with meticillin-resistant S. aureus endocarditis

Andrew Kirby1,2, Kavya Mohandas1, Caroline Broughton2, Timothy J. Neal1, Godfrey W. Smith1, Pearl Pai3 and Carlos Nistal de Paz1

1 Department of Medical Microbiology, Royal Liverpool & Broadgreen University Hospital Trust, Prescot Street, Liverpool, Merseyside L7 8XP, UK

2 Department of Infection & Host Defence, Liverpool University, 8th Floor Duncan Building, Daulby Street, Liverpool L69 3GA, UK

3 Department of Nephrology, Royal Liverpool & Broadgreen University Hospital Trust, Prescot Street, Liverpool, Merseyside L7 8XP, UK

Correspondence
Andrew Kirby
amk{at}liv.ac.uk

Received September 10, 2008
Accepted November 12, 2008

We report a patient who developed a meticillin-resistant Staphylococcus aureus (MRSA) central venous catheter infection complicated by infective endocarditis. The patient was initially treated with glycopeptides, which led to the development of heterogeneous glycopeptide resistance, the detection of which required the use of a macro Etest screening test. Subsequently, the causative strain, confirmed by PFGE as a UK epidemic MRSA-15, was treated with daptomycin, and again resistance developed in vivo. The development in vivo of resistance to both these agents suggests that the resistance mechanisms may be associated. We suggest that the clinician managing MRSA infection should anticipate daptomycin resistance when reduced glycopeptide susceptibility is detected.

Abbreviations: BSAC, British Society for Antimicrobial Chemotherapy; hGISA, heterogeneous glycopeptide-intermediate Staphylococcus aureus; i.v., intravenous; MRSA, meticillin-resistant S. aureus; TOE, transoesophageal echocardiograph; TTE, transthoracic echocardiogram.




This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
A. Kirby, R. Graham, N. J. Williams, M. Wootton, C. M. Broughton, M. Alanazi, J. Anson, T. J. Neal, and C. M. Parry
Staphylococcus aureus with reduced glycopeptide susceptibility in Liverpool, UK
J. Antimicrob. Chemother., February 2, 2010; (2010): dkq009v1 - dkq009.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
INT J SYST EVOL MICROBIOL J MED MICROBIOL MICROBIOLOGY J GEN VIROL ALL SGM JOURNALS
Copyright © 2009 Society for General Microbiology.